Cantor Fitzgerald Keeps Their Buy Rating on Innoviva (INVA)
Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Innoviva yesterday and set a price target of $31.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Seedhouse is a 4-star analyst with an average return of 11.5% and a 44.69% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Xencor, Astria Therapeutics, and Innoviva.
Currently, the analyst consensus on Innoviva is a Moderate Buy with an average price target of $36.60.
Based on Innoviva’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $107.8 million and a net profit of $89.91 million. In comparison, last year the company earned a revenue of $89.51 million and had a net profit of $1.21 million
Read More on INVA:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.